NEW YORK and LEAMINGTON, Ontario - Tilray Brands Inc. (NASDAQ:TLRY; TSX:TLRY) announced Wednesday the acquisition of Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform, according to a press release statement.
Lyphe has dispensed approximately 150,000 units to date, while Lyphe Clinic has treated over 16,000 patients. The acquisition establishes Tilray Medical’s first vertically integrated patient-centric medical platform in the UK, combining pharmaceutical-grade cannabis cultivation with clinical care and dispensing services.
The company expects the Lyphe business to be accretive in 2027. Tilray will use CC Pharma’s purchasing power to supply medications through the Lyphe platform. The acquisition comes as analysts predict Tilray will turn profitable this year, with earnings per share forecast at $1.67 for fiscal 2026, according to InvestingPro data. The company maintains a current ratio of 2.79, indicating liquid assets comfortably exceed short-term obligations.
Tilray also filed an at-the-market equity program of up to $180 million to support its global beverage platform expansion. The ATM program will be managed by Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners LLC. Shares will be offered through a prospectus supplement and base prospectus under registration statement Form S-3 (File No. 333-26778
. Trading at $6.91, the stock has declined 59% over six months, though InvestingPro analysis suggests the company may be undervalued at current levels.
The company acquired BrewDog six weeks ago and expects the business to be cash flow positive in 2027. Tilray plans to invest in revitalizing BrewDog’s brewpub estate and will launch HiBall Energy in the UK in May.
Tilray stated it is monitoring U.S. medical cannabis rescheduling and evaluating participation in a Center for Medicare and Medicaid Innovation pilot program to supply hemp-derived medical cannabis to underserved patients.
The company operates in over 20 countries with more than 40 brands across cannabis, beverage and wellness sectors.
In other recent news, Tilray Brands Inc. reported strong financial results for the third quarter of fiscal year 2026, ending February 28, with notable improvements in both revenue and net income. This performance highlights the company’s ability to grow despite challenges within the industry. Additionally, Tilray announced the launch of PORTAL, a new cannabis brand aimed at experienced consumers with high tolerance levels. The product line includes infused pre-rolls and vape cartridges with high THC content. In another development, Roth/MKM upgraded Tilray’s stock from Neutral to Buy, citing the company’s stable Canadian business and improved international operations. The firm maintained a price target of $10.00 for the stock. Roth/MKM also noted that CC Pharma has become a beneficial asset for Tilray. These recent developments underscore Tilray’s ongoing efforts to expand its market presence and optimize operational efficiencies.
Lyphe has dispensed approximately 150,000 units to date, while Lyphe Clinic has treated over 16,000 patients. The acquisition establishes Tilray Medical’s first vertically integrated patient-centric medical platform in the UK, combining pharmaceutical-grade cannabis cultivation with clinical care and dispensing services.
The company expects the Lyphe business to be accretive in 2027. Tilray will use CC Pharma’s purchasing power to supply medications through the Lyphe platform. The acquisition comes as analysts predict Tilray will turn profitable this year, with earnings per share forecast at $1.67 for fiscal 2026, according to InvestingPro data. The company maintains a current ratio of 2.79, indicating liquid assets comfortably exceed short-term obligations.
Tilray also filed an at-the-market equity program of up to $180 million to support its global beverage platform expansion. The ATM program will be managed by Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners LLC. Shares will be offered through a prospectus supplement and base prospectus under registration statement Form S-3 (File No. 333-26778
. Trading at $6.91, the stock has declined 59% over six months, though InvestingPro analysis suggests the company may be undervalued at current levels.The company acquired BrewDog six weeks ago and expects the business to be cash flow positive in 2027. Tilray plans to invest in revitalizing BrewDog’s brewpub estate and will launch HiBall Energy in the UK in May.
Tilray stated it is monitoring U.S. medical cannabis rescheduling and evaluating participation in a Center for Medicare and Medicaid Innovation pilot program to supply hemp-derived medical cannabis to underserved patients.
The company operates in over 20 countries with more than 40 brands across cannabis, beverage and wellness sectors.
In other recent news, Tilray Brands Inc. reported strong financial results for the third quarter of fiscal year 2026, ending February 28, with notable improvements in both revenue and net income. This performance highlights the company’s ability to grow despite challenges within the industry. Additionally, Tilray announced the launch of PORTAL, a new cannabis brand aimed at experienced consumers with high tolerance levels. The product line includes infused pre-rolls and vape cartridges with high THC content. In another development, Roth/MKM upgraded Tilray’s stock from Neutral to Buy, citing the company’s stable Canadian business and improved international operations. The firm maintained a price target of $10.00 for the stock. Roth/MKM also noted that CC Pharma has become a beneficial asset for Tilray. These recent developments underscore Tilray’s ongoing efforts to expand its market presence and optimize operational efficiencies.
TILRAY LYPHE UK LTD overview - Find and update company information - GOV.UK
TILRAY LYPHE UK LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activityfind-and-update.company-information.service.gov.uk
. ( Edinburgh caterer A Crolla & Son)
